Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HTR2A | P28223 | 4/20 | 0.36 |
| ▸ | HRH1 | P35367 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | ACP1 | P24666 | 1/20 | 0.34 |
| ▸ | CDC25B | P30305 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4663307 | 0.87 | ALDH1A1 (0.43) | MAPTALDH1A1HSD17B10PTPN1ACP1 | |
| SCHEMBL4665140 | 0.84 | CYP2D6 (0.45) | MAPTALDH1A1HTR2AHSD17B10L3MBTL1 | |
| SCHEMBL4664735 | 0.81 | ALDH1A1 (0.41) | MAPTALDH1A1HSD17B10PTPN1ACP1 | |
| SCHEMBL4662962 | 0.81 | HTR2A (0.39) | MAPTALDH1A1HTR2AHRH1PTPN1 | |
| SCHEMBL4664811 | 0.81 | ALDH1A1 (0.40) | MAPTALDH1A1L3MBTL1PTPN1ACP1 | |
| SCHEMBL4664703 | 0.78 | HTR2A (0.37) | MAPTALDH1A1HTR2AHRH1PTPN1 | |
| SCHEMBL4663008 | 0.78 | EPHX2 (0.47) | EPHX2PTPN1ACP1CDC25B | |
| SCHEMBL4664944 | 0.78 | PTPN1 (0.44) | MAPTALDH1A1PTPN1ACP1CDC25B | |
| SCHEMBL4664852 | 0.76 | TDP1 (0.49) | MAPTALDH1A1L3MBTL1PTPN1ACP1 | |
| SCHEMBL4666748 | 0.75 | ALDH1A1 (0.44) | MAPTALDH1A1HSD17B10PTPN1ACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132562-A1 | TETRONIC AND TETRAMIC ACIDS | GODEL THIERRY | 2008-06-05 | — | — | US | claimed |
| US-20050119329-A1 | Tetronic and tetramic acids | HOFFMANN-LA ROCHE INC. | 2005-06-02 | — | — | US | claimed |
| US-20080132562-A1 | TETRONIC AND TETRAMIC ACIDS | GODEL THIERRY | 2008-06-05 | — | — | US | disclosed |
| US-20050119329-A1 | Tetronic and tetramic acids | HOFFMANN-LA ROCHE INC. | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132562-A1 | TETRONIC AND TETRAMIC ACIDS | BACE1, PSEN1, BACE2 | MAPT 74/4885ALDH1A1 2826/4885HTR2A 2974/4885 |
| US-20050119329-A1 | Tetronic and tetramic acids | BACE1, PSEN1, BACE2 | MAPT 74/4885ALDH1A1 2826/4885HTR2A 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.